-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rebyota in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rebyota in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rebyota in Crohn's Disease (Regional Enteritis) Drug Details: Fecal microbiota,...
-
Product Insights
NewHepatic Encephalopathy – Drugs In Development, 2024
Empower your strategies with our Hepatic Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions. Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load),...
-
Product Insights
NewClostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2024
Empower your strategies with our Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or "C. diff", a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection include watery diarrhea with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool, and weight loss. Risk...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBX-7455 in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBX-7455 in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBX-7455 in Crohn's Disease (Regional Enteritis) Drug Details: RBX-7455 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBX-7455 in Hepatic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBX-7455 in Hepatic Encephalopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBX-7455 in Hepatic Encephalopathy Drug Details: RBX-7455 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-4804 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-4804 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-4804 in Ulcerative Colitis Drug Details: JNJ-4804 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBX-7455 in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RBX-7455 in Clostridioides difficile Infections (Clostridium difficile Associated Disease) Drug Details: RBX-7455 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risperidone ER in Schizoaffective Disorder
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Risperidone ER in Schizoaffective Disorder Drug Details: Risperidone ER is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VB-1016 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-1016 in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-1016 in Cervical Cancer Drug Details: VB-1016 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rebyota in Crohn’s Disease (Regional Enteritis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Rebyota in Crohn's Disease (Regional Enteritis) Drug Details:Fecal microbiota, live-jslm (Rebyota) is an opaque first fecal...